Cargando…
Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment
Purpose: To assess the utility of measurement of the computed tomography (CT) attenuation value (CTav) in predicting tumor necrosis in hepatocellular carcinoma (HCC) patients who achieve a complete response (CR), defined using modified Response Evaluation Criteria in Solid Tumors (mRECIST), after le...
Autores principales: | Chuma, Makoto, Yokoo, Hideki, Hiraoka, Atsushi, Ueda, Kazuhiko, Yokoyama, Takahiro, Tsuji, Kunihiko, Shimada, Noritomo, Uojima, Haruki, Kobayashi, Satoshi, Hattori, Nobuhiro, Okubo, Tomomi, Atsukawa, Masanori, Ishikawa, Toru, Takaguchi, Koichi, Tsutsui, Akemi, Toyoda, Hidenori, Tada, Toshifumi, Saito, Yoshinori, Hirose, Shunji, Tanaka, Takaaki, Takeda, Kazuhisa, Otani, Masako, Sekikawa, Zenjiro, Watanabe, Tsunamasa, Hidaka, Hisashi, Morimoto, Manabu, Numata, Kazushi, Kagawa, Tatehiro, Sakamoto, Michiie, Kumada, Takashi, Maeda, Shin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139739/ https://www.ncbi.nlm.nih.gov/pubmed/35621656 http://dx.doi.org/10.3390/curroncol29050266 |
Ejemplares similares
-
Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting
por: Fukushima, Taito, et al.
Publicado: (2021) -
A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma
por: Kobayashi, Satoshi, et al.
Publicado: (2022) -
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
por: Chuma, Makoto, et al.
Publicado: (2020) -
Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response
por: Toyoda, Hidenori, et al.
Publicado: (2021) -
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2018)